Discussion on End-User Research for MPT R&D
The Initiative for Multi-Purpose Technologies (IMPT) has published these remarks on the role of end-user research in the development of multi-purpose technologies (MPTs). Leading experts, including AVAC’s Anabel Gomez, reflect on considerations for applying this research effectively while framing a few central questions it can address.
December 21, 2017 — IMPT
Six Lessons in Helping African Women Avoid HIV
Sixshort videosdescribe how a Kenyan nonprofit organization tackles one of Africa’s toughest missions: helping young women protect themselves against HIV.
December 15, 2017 — The New York Times
The past, present, and future of HIV funding
A Kaiser Family Foundation web briefing navigated the HIV/AIDS funding landscape, taking a look at trends over time, the latest data, and what we might expect in the future. When analyzing federal funding by the US government for HIV both home and abroad since the first AIDS cases were identified in 1981, “you notice a very dramatic, steep rise at different points, and generally a rise over time,” said Jen Kates, vice president, director of global health and HIV policy, Kaiser Family Foundation.
December 11, 2017 — AJMC
AVAC Policy Director Kevin Fisher on funding the AIDS response
AVAC Policy Director Kevin Fisher appeared onCGTNto discuss the role of governments and private industry in addressing prevention, the search for a cure, and overall costs.
December 6, 2017 — CGTN America
In the Future, A Simple Ring Could Protect You from HIV and Unwanted Pregnancies
About a dozen new types of microbicides are in the research pipeline, including some that could protect women against not only HIV infection but also other sexually transmitted infections and unwanted pregnancies. But this progress is in peril.
November 23, 2017 — Bhekisisa
48th Union World Conference: Good participatory practice guidelines come to TB vaccine development
Describing the value of working with funders, sponsors, industry partners, governments and community members during all stages of tuberculosis vaccine research and development, theGood Participatory Practice Guidelines for TB Vaccine Researchreleased the first day of this conference is the latest step in a movement to ensure those most affected by science inform its discoveries.
October 17, 2017 — Science Speaks
IDWeek 2017 HIV Science Preview
With the annual IDWeek conference fast approaching, thousands of leading physicians and researchers will once again gather to learn about cutting-edge research on HIV prevention, treatment and cures—and to discuss how to apply that research in ways that can directly benefit people living with HIV today.
September 29, 2017 — BodyPro
Progress Reported on Monthly HIV Shot
A clinical trial published in theLancetshowed a new injectable antiretroviral therapy (ART) given every four or eight weeks may be just as effective as the daily oral medications that are currently used to keep the virus under control.
August 17, 2017 — Healthline
How a Blue Pill Is Stopping the Spread of HIV
Thirty-six years after a rare lung infection in gay men in Los Angeles heralded the start of the AIDS epidemic, more than half of all people living with HIV are on virus-suppressing treatment. And thousands of people are using Gilead Sciences’ Truvada in a PrEP trial that’s curbing the spread in communities from London to San Francisco.
August 17, 2017 — Bloomberg
PrEP Trials: The benefits—and challenges—of seeking community input
Last fall, Gilead came under fire from community activists for rolling out the DISCOVER trials for Descovy (TAF/FTC) as PrEP without adequately involving community advisors per the Good Participatory Practice (GPP) guidelines. Community advocate and clinical investigator pushback led to some changes in the trial protocol, [but]…according to Jeremiah Johnson, community engagement coordinator for Treatment Action Group (TAG),…other concerns remain.
August 7, 2017 — The Body
J&J Moves One Step Closer to a Potential Vaccine for HIV
Healthcare giant Johnson & Johnson is to take a big step closer to inventing a vaccine for HIV when it publishes the results of a groundbreaking clinical trial this week.
July 23, 2017 — Telegraph
What’s Changed Since the Last HIV Meeting?
As the world’s top HIV experts head to Paris for an International AIDS Society meeting, word is we’re still playing catch-up with the virus. And if resistance to antiretroviral drugs grows, things will only get worse.
July 20, 2017 — Deutsche Welle
AIDS Deaths are Almost Half of What They Were in 2005 — But Experts Worry Trump Could Reverse That
A new report from the United Nations shows promising progress in treating the global HIV/AIDS crisis, but some experts worry President Donald Trump’s policy proposals might turn the trend right back around.
July 20, 2017 — Mic
Threatened HIV Funding Cuts in Limelight at IAS 2017
Researchers, clinicians, and advocates converging in Paris for the International AIDS Conference 2017 will not only be talking about new HIV treatment and prevention and how to roll out innovative medications in a comprehensive, integrated way, they will also be making a case to funders….”If funders feel the progress we’re making, it will create dividends in more ways than one,” said International AIDS Society President Linda-Gail Bekker. “We may see some threatened cuts put on hold.”
July 19, 2017 — Medscape
Surprise FDA Approval of Generic Truvada Is a ‘Wakeup Call’ for Activists
The surprise approval of generic Truvada (tenofovir disoproxil fumarate and emtricitabine) by the US Food and Drug Administration (FDA) on June 9 left patients, advocates and doctors scrambling to understand exactly when the generic will become available and how much it will cost.
July 6, 2017 — The Body
HIV Testing: A portal for treatment and prevention
Mitchell Warren calls, on National HIV Testing Day, for individuals to get tested, know their status and take appropriate steps to access treatment and prevention. And also for funders and policymakers to support life-saving and cost-saving testing programs that are the cornerstone of a comprehensive, integrated and sustained response to HIV.
June 27, 2017 — TheBody.com
FDA Approves First Generic Truvada in US
The US Food and Drug Administration (FDA) has approved the first generic version of emtricitabine/tenofovir disoproxil (Truvada, Gilead Sciences) to both treat and prevent HIV infections in this country, the agency announced today.
June 9, 2017 — Medscape
Trump Administration’s Budget Criticized by Medical and Health Advocacy Groups Wary of Cuts
Medical and health advocacy groups have come out largely in opposition to the Trump administration’s proposed cuts in the 2018 budget, with one executive calling it a “disaster” to federal programs and institutions that provide resources to improve health.
May 24, 2017 — Healthcare Finance
Gay in Nigeria: The stark reality for LGBT people in the West African country
Activist Micheal Ighodaro speaks about being violently attacked in his home city, seeking asylum in the US and the issues that LGBT people across the world.
May 23, 2017 — Independent
Advocacy in Uncertain Times: HIV Vaccine Awareness Day turns 20
The hard truth is we will pass many more May 18ths before we can celebrate a licensed accessible HIV vaccine. And HIV vaccine research can only succeed with enduring advocacy and fresh voices taking up the charge. That means the next generation of vaccine champions will need to rise to the challenge of keeping the hope for and need for an HIV vaccine in the forefront of HIV advocacy.
May 18, 2017 — The Huffington Post
Gilead Slowly Rolls out Ads for Truvada for PrEP — 4 Years after Approval
Gradually ramping up promotion of its HIV-prevention pill, Gilead Sciences has turned to humor, dating apps and social media sites like Tumblr and Snapchat to raise awareness about HIV prevention.
May 3, 2017 — MM&M
HIV, Family Planning Groups Grapple with New WHO Guidance on Popular Contraceptive
The World Health Organization’s reclassification last month of progestogen-only injectable contraceptives has triggered a critical debate in the family planning community over how to manage the potential link between higher rates of HIV acquisition and one of the most popular birth control methods in many at-risk communities.
April 4, 2017 — Devex
HIV Vaccines: where are we now?
A vaccine for HIV has been sought since the early days of the epidemic. After years of difficulties and setbacks, several new approaches are providing cause for optimism.
April 1, 2017 — Lancet
Curse or Conundrum? Drawing New Donors When a Big Name is at the Table
While the Gates Foundation encourages its grantees to diversify, it is often difficult for organizations that get Gates’ funding early on to attract other donors. This is because of a perception that they do not need further support, Peter Matlon, an expert in agricultural development, said in front of the audience at the American Enterprise Institute.
March 31, 2017 — Devex
40 Organizations Protest in Front of White House on International Women’s Day
Today, the National LGBTQ Task Force joined 40 national organizations in taking part in a protest in front of the White House against President Donald Trump’s global gag rule.
March 8, 2017 — LGBT Weekly
To Combat HIV, Sub-Saharan Africa Must Strengthen Its Data Management Systems
In an interview on behalf of IFARA at CROI 2017, Kevin Fisher spoke with Ian Sanne and Kevin De Cock about HIV in sub-Saharan Africa.
March 6, 2017 — BodyPro
Community Engagement in HIV Prevention Is a Disaster Management Plan
In an interview on behalf of IFARA at CROI 2017, Morenike Ukpong-Folayan spoke with Mark Hubbard and Stacey Hannah about addressing community concerns regarding medical research.
March 6, 2017 — BodyPro
How Access to HIV Treatment is Being Transformed Through Innovation
One benefit of a “test and treat” approach is that it reduces the amount of virus in carriers’ bodies and so lowers their chances of passing it on. But despite big health benefits, the “test and treat” approach throws up new challenges for countries with large HIV epidemics.
March 2, 2017 — The Guardian
Five HIV Patients Left ‘Virus-Free’ with No Need for Daily Drugs in Early Vaccine Trials
A new vaccine-based treatment for HIV has succeeded in suppressing the virus in five patients, raising hopes further research could help prevent AIDS without the need for daily drugs. Researchers combined two innovative HIV vaccines with a drug usually used to treat cancer in the trial… After receiving the treatment, the virus was undetectable in five out of 24 participants and its spread was stopped by their immune systems, reported theNew Scientist. One of them has been drug-free for seven months.
February 24, 2017 — Independent
PEPFAR Trumps Politics: US advocates push to save global AIDS funding
The battle to save the US President’s Emergency Plan for AIDS Relief (PEPFAR) is already well underway, just one month after President Donald J. Trump’s inauguration and his almost immediate reinstatement of the country’s global gag order on foreign funding for comprehensive sexual health services.
February 22, 2017 — POZ
Jared Baeten—Aiming to See Off HIV
“The last person that I train, I want that training to be in something other than HIV”, says Jared Baeten. Speaking toThe Lancet Infectious Diseases from the HIV Research for Prevention Conference (HIVR4P) in Chicago, IL, USA, where he has brought a 12-strong team of his researchers, Baeten explains: “When that time comes, I want HIV to have been eliminated as public health threat, so we can focus on other diseases”.
January 3, 2017 — Lancet
→ Continue through the archives. Find articles from 2016 and older.